- Trial phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Why 4/10
- TUDRIQEV is already approved and commercially launched with no pending PDUFA or pivotal readout for this drug in the next ~12 months. The defining binary binary (approval) has already passed. The next catalysts are commercial execution and the confirmatory Phase 3 trial, neither of which is a hard dated binary event in the near term.
TUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
Price Chart
Executive Summary
TUDRIQEV (vusolimogene oderparepvec, formerly RP1) is Replimune's first commercial product and only the second oncolytic virus therapy ever approved in the U.S. It won FDA accelerated approval on August 6, 2026 for advanced cutaneous melanoma in combination with nivolumab, after a turbulent regulatory journey that included two Complete Response Letters and a 10-3 AdComm vote. The drug launched commercially on October 1, 2026, with early traction of over 15 prescribing institutions. Replimune remains unprofitable (net loss of $57M in Q2 FY2027) and faces the risk that the required confirmatory Phase 3 trial may not validate the accelerated approval. The stock has rebounded from a low of ~$1.70 after the April 2026 CRL to ~$23.28, roughly in line with the analyst consensus price target.
How It Works
TUDRIQEV is a genetically modified herpes simplex virus designed to infect and kill cancer cells directly (oncolysis). It is injected directly into tumors, where it replicates inside cancer cells, causing them to burst. This process also stimulates the immune system to recognize and attack cancer cells throughout the body. It is used in combination with nivolumab (Opdivo), a PD-1 checkpoint inhibitor.
Trial Status
Approved by the FDA on August 6, 2026 under accelerated approval based on the Phase 1/2 IGNYTE trial (NCT03767348). In the registrational cohort of 140 patients with advanced melanoma who progressed on anti-PD-1 therapy, TUDRIQEV plus nivolumab showed a confirmed objective response rate (ORR) of 32.9% with a median duration of response of 33.7 months (per AJMC). A confirmatory Phase 3 trial is required and ongoing as a condition of the accelerated approval. The drug was commercially launched on October 1, 2026, with first patient dosed on October 6, 2026.
The Two-Sided Case
Upcoming Catalysts
- Commercial sales trajectory updates (next quarterly earnings around late January 2027)
- Permanent J-code expected by April 2027 (facilitates reimbursement)
- Confirmatory Phase 3 trial data readout (timing not yet specified)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Replimune Group, Inc. CLUSTER REPL ·Originating report